HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
3,5- bis(acetoxyacetylamino)- 4- chlorobenzonitrile
may regulate allergic inflammation by the suppression of histamine release enhanced by interleukin 3
Also Known As:
TYB 2285; TYB-2285; Acetamide, N,N'-(2-chloro-5-cyano-1,3-phenylene)bis(2-(acetyloxy))-
Networked:
10
relevant articles (
0
outcomes,
4
trials/studies)
Bio-Agent Context: Research Results
Organic Chemicals: 133
Nitriles: 227
3,5-bis(acetoxyacetylamino)-4-chlorobenzonitrile: 10
Related Diseases
1.
Respiratory Hypersensitivity
08/01/1998 - "
7. The present study shows that TYB-2285 inhibits late asthmatic response and airway hyperresponsiveness, presumably by inhibiting the accumulation and activation of eosinophils and other inflammatory cells.
"
08/01/1998 - "
This airway hyperresponsiveness was reversed by a single administration of TYB-2285.
"
11/01/1994 - "
Additionally, airway hyper-responsiveness was also reversed by the single administration of TYB-2285.
"
11/01/1994 - "
The present study suggests that TYB-2285 inhibits late asthmatic response and airway hyperresponsiveness by inhibiting the accumulation of eosinophils and other inflammatory cells into the airway, and also by inhibiting the production of oxygen radicals from airway-infiltrated cells.
"
02/01/1996 - "
When TYB-2285 (100 mg/kg) was given at 16 and 2 h before the challenge, the early response, the late response and the post antigen-induced airway hyperresponsiveness (AHR) as indicated by a decrease in the PC400 was inhibited significantly.
"
2.
Asthma (Bronchial Asthma)
06/01/1997 - "
Effect of TYB-2285 and its metabolites on immune responses by peripheral blood mononuclear cells (PBMC) from children with bronchial asthma was investigated.
"
07/01/1998 - "
Compound 5c is now under investigation in Japan as TYB-2285 (Figure 1) for asthma and atopic dermatitis in phase II clinical studies.
"
06/01/1997 - "
Taken, together, TYB-2285 could work as a weak immunosuppressant to modify lymphocytes' responses to allergen in patients with bronchial asthma.
"
06/01/1997 - "
[Immunomodulation by TYB-2285 of Dermatophagoides farinae (Df) antigen-induced IFN-gamma and IL-4 production in lymphocytes from children with bronchial asthma].
"
3.
Anaphylaxis (Anaphylactic Shock)
08/01/1998 - "
Effect of TYB-2285 on peritoneal anaphylaxis in passively sensitized rats.
"
02/01/1997 - "
4. TYB-2285 (30 mg/kg p.o.) inhibited the accumulation of neutrophils during the late phase of lung anaphylaxis significantly without a significant change in total cells.
"
02/01/1997 - "
1. We examined the effect of TYB-2285 on the acute phase and the late phase of lung anaphylaxis in rats.
"
02/01/1997 - "
Effect of TYB-2285 on lung anaphylaxis in actively sensitized rats.
"
02/01/1997 - "
2. TYB-2285 (3-30 mg/kg PO) inhibited antigen-induced bronchoconstriction and TxB2 production during the acute phase of lung anaphylaxis in a dose-dependent manner.
"
4.
Atopic Dermatitis (Atopic Eczema)
07/01/1998 - "
Compound 5c is now under investigation in Japan as TYB-2285 (Figure 1) for asthma and atopic dermatitis in phase II clinical studies.
"
5.
Inflammation (Inflammations)
09/01/1993 - "
5. These results demonstrate that TYB-2285 inhibits the histamine release primed with IL-3 and also suggests that TYB-2285 might regulate allergic inflammation in vivo by the suppression of mediator release primed with IL-3.
"
03/01/1993 - "
4. Histamine release in the absence of rIL-3 was not inhibited by TYB-2285 or DSCG at concentrations less than 1 mM. 5. From these results, it is suggested that TYB-2285 and DSCG might regulate allergic inflammation by the suppression of mediator release enhanced by IL-3.
"
Related Drugs and Biologics
1.
Antigens
2.
Reactive Oxygen Species (Oxygen Radicals)
3.
Dihydrotachysterol (AT 10)
4.
Interleukin-3 (Interleukin 3)
5.
amlexanox (Aphthasol)
6.
Interleukin-4 (Interleukin 4)
7.
Serotonin (5 Hydroxytryptamine)
8.
Ovalbumin
9.
Ketotifen (Ketotifene)
10.
Immunosuppressive Agents (Immunosuppressants)
Related Therapies and Procedures
1.
Immunomodulation